Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Improving emotional health assessment in patients with kidney cancer

Eric Jonasch • 30 May 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer

Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the need for more sophisticated tools to assess emotional health in patients with kidney cancer, highlighting that current surveys are not granular enough to identify individuals who may require intervention. It is essential to develop more detailed assessments that go beyond simple scales to better understand patients’ experiences and provide targeted support. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Jonasch

Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
Evaluating the evolving role of belzutifan in renal cell carcinoma
1:13
Evaluating the evolving role of belzutifan in renal cell carcinoma
Eric Jonasch • 1 Jun 2025
STARLITE-1: 177Lu-Girentuximab, cabozantinib & nivolumab in ccRCC
0:54
STARLITE-1: 177Lu-Girentuximab, cabozantinib & nivolumab in ccRCC
Eric Jonasch • 1 Jun 2025
5-year follow-up results from LITESPARK-004
0:54
5-year follow-up results from LITESPARK-004
Eric Jonasch • 1 Jun 2025

Related Videos

Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Future directions in prostate cancer from the PROTEUS trial
1:08
Future directions in prostate cancer from the PROTEUS trial
Mary-Ellen Taplin • 29 May 2026
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026
The content of VJOncology is intended for healthcare professionals